• Radiopharm Theranostics completed enrollment in a U.S. Phase 2b imaging trial of RAD 101 for diagnosing recurrent brain metastases.
• Interim results have already been presented, indicating RAD 101 findings broadly matched standard MRI assessments.
• Primary endpoint results will be presented in June 2026.
• Radiopharm plans to advance RAD 101 into a U.S. Phase 3 pivotal trial, positioning program for potential regulatory discussions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-044334), on April 16, 2026, and is solely responsible for the information contained therein.